+++ Einfach investieren ▪ mit Kapitalschutz oder Teilschutz ▪ raiffeisenzertifikate.at ▪ jetzt in Zeichnung +++ -w-
26.09.2017 22:01:00

OncoSec to Present at the Cantor Fitzgerald Global Healthcare Conference

SAN DIEGO, Sept. 26, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that Punit Dhillon, CEO and President of OncoSec, will present at the Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2017 at 4:35 PM ET / 1:35 PM PT. The conference will take place at the Intercontinental New York Barclay Hotel.

To view the live webcast, please access the following link at the time of the presentation: http://wsw.com/webcast/cantor6/oncs. An archived version of the webcast will be available for 90 days on OncoSec's website: http://www.oncosec.com 

About OncoSec Medical Incorporated 
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer. ImmunoPulse® is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors and has shown the potential to reach beyond the site of local treatment to initiate a systemic immune response. ImmunoPulse® IL-12, OncoSec's lead program, is currently in clinical development for metastatic melanoma and triple-negative breast cancer. The program's current focus is on the significant unmet medical need in patients with melanoma who are refractory or have relapsed on anti-PD-1 therapies. In addition to ImmunoPulse® IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse® platform. For more information, please visit www.oncosec.com.

CONTACT:
Investor Relations 
OncoSec Medical Incorporated
855-662-6732
investors@oncosec.com

Media Relations 
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com

OncoSec Medical, Inc. Logo. Please visit http://oncosec.com/ for more information. (PRNewsFoto/OncoSec Medical, Inc.) (PRNewsfoto/OncoSec Medical Incorporated)

 

View original content with multimedia:http://www.prnewswire.com/news-releases/oncosec-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-300526031.html

SOURCE OncoSec Medical Incorporated

Nachrichten zu OncoSec Medical Incmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu OncoSec Medical Incmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!